

CNS SPECTRUMS®

THE INTERNATIONAL JOURNAL OF NEUROPSYCHIATRIC MEDICINE

ORIGINAL RESEARCH

Disordered Gambling Among Racial and Ethnic Groups in the US: Results From the National Epidemiologic Survey on Alcohol and Related Conditions

A.A. Alegría, N.M. Petry, D.S. Hasin, S-M. Liu, B.F. Grant, and C. Blanco

An Integrated Analysis of the Efficacy of Desvenlafaxine Compared with Placebo in Patients with Major Depressive Disorder

M.E. Thase, S.G. Kornstein, J-M. Germain, Q. Jiang, C. Guico-Pabia, and P.T. Ninan

CASE REPORTS

Caffeine-Induced Psychosis

D.W. Hedges, F.Y. Woon, and S.P. Hoopes

Anorexia Nervosa in Identical Triplets

M.S. Sokol, A.K. Carroll, D.M. Heebink, K.M. Hoffman-Rieken, C.S. Goudge, and D.D. Ebers

PEARLS IN CLINICAL NEUROSCIENCE

Bipolar Disorder: Emotional Dysregulation and Neuronal Vulnerability

D.J. Stein, N. Horn, R. Ramesar, and J. Savitz

COMMUNIQUE

Computerized Neuropsychological Assessments: *Pros and Cons*



ADHD with oppositional symptoms

As important to treat as it is to discuss

Oppositional symptoms—
the missing piece of the ADHD
symptom discussion

40% to 60% of children with ADHD present with oppositional symptoms.²⁻⁵ Many parents, however, are not aware of the relationship of these symptoms and ADHD or how they can exacerbate the disorder.⁶

40% to 60%
of children with ADHD
present with
oppositional symptoms²⁻⁵

How many of these patients are in your practice?

Initiating frank and open discussions with parents and using diagnostic tools that include oppositional symptoms may further refine a comprehensive treatment plan for ADHD with oppositional symptoms.

Start the discussion to help manage oppositional symptoms and address what was once left unsaid.

References: 1. Conners CK. Conners 3™—parent. North Tonawanda, NY: Multi-Health Systems Inc; 2008. 2. Elia J, Ambrosini P, Berrettini W. ADHD characteristics: I. Concurrent co-morbidity patterns in children & adolescents. *Child Adolesc Psychiatr Ment Health*. 2008;2:15. <http://www.capmh.com/content/2/1/15>. Accessed January 20, 2009. 3. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. *Arch Gen Psychiatry*. 1999;56:1073-1086. 4. Attention-deficit disorders with oppositionality and aggression. In: Brown TE, ed. *Attention-Deficit Disorders and Comorbidities in Children, Adolescents, and Adults*. Arlington, VA: American Psychiatric Publishing, Inc; 2000. 5. Biederman J, Faraone SV, Milberger S, et al. Is childhood oppositional defiant disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up study of children with ADHD. *J Am Acad Child Adolesc Psychiatry*. 1996;35:1193-1204. 6. Findling RL, Connor DF, Wigal T, Eagan C, Onofrey MN. A linguistic analysis of in-office dialogue among psychiatrists, parents, and child and adolescent patients with ADHD. *J Attent Disord*. 2008. <http://jadsagepub.com/cgi/content/abstract/1087054708323002v1>. Accessed September 2, 2008.

EDITORS

EDITOR

Eric Hollander, MD
Institute of Clinical Neuroscience
New York, NY

INTERNATIONAL EDITOR

Joseph Zohar, MD
Chaim Sheba Medical Center
Tel-Hashomer, Israel

ASSOCIATE INTERNATIONAL EDITORS

EUROPE

Donatella Marazziti, MD
University of Pisa
Pisa, Italy

MID-ATLANTIC

Dan J. Stein, MD, PhD
University of Cape Town
Cape Town, South Africa

ASIA

Shigeto Yamawaki, MD, PhD
Hiroshima University School
of Medicine
Hiroshima, Japan

CONTRIBUTING WRITERS

Analuća A. Alegría, BA
Dawson W. Hedges, MD
Mae S. Sokol, MD
Michael E. Thase, MD

FIELD EDITOR

Michael Trimble, MD, FRCP, FRPsych

COLUMNISTS

Uriel Halbrich, MD
Stefano Pallanti, MD, PhD
Thomas E. Schlaepfer, MD
Stephen M. Stahl, MD, PhD
Dan J. Stein, MD, PhD

CME COURSE DIRECTOR

James C.-Y. Chou, MD

SUPPLEMENT EDITOR

Joseph Zohar, MD

EDITORIAL ADVISORY BOARD

NEUROLOGISTS

Mitchell F. Brin, MD
University of California, Irvine
Irvine, CA
Jeffrey L. Cummings, MD
University of California, Los Angeles
Los Angeles, CA
Jerome Engel, Jr., MD, PhD
University of California, Los Angeles
Los Angeles, CA
Mark S. George, MD
Medical University of South Carolina
Charleston, SC
Richard B. Lipton, MD
Albert Einstein College of Medicine
Bronx, NY
C. Warren Olanow, MD, FRCP
Mount Sinai School of Medicine
New York, NY
Steven George Pavlakis, MD
Maimonides Medical Center
Brooklyn, NY
Stephen D. Silberstein, MD, FACP
Thomas Jefferson University
Philadelphia, PA
Michael Trimble, MD, FRCP, FRPsych
National Hospital for Neurology
and Neurosurgery
London, United Kingdom

PSYCHIATRISTS

Dennis S. Charney, MD
Mount Sinai School of Medicine
New York, NY
Dwight L. Evans, MD
University of Pennsylvania
Philadelphia, PA
Siegfried Kasper, MD
University of Vienna
Vienna, Austria
Martin B. Keller, MD
Brown Medical School
Providence, RI
Lorin M. Koran, MD
Stanford University School of Medicine
Stanford, CA
Yves Lecrubier, MD
Hôpital de la Salpêtrière
Paris, France
Herbert Y. Meltzer, MD
Vanderbilt University Medical Center
Nashville, TN
Stuart A. Montgomery, MD
St. Mary's Hospital Medical School
London, United Kingdom
Charles B. Nemeroff, MD, PhD
Emory University School of Medicine
Atlanta, GA
Humberto Nicolini, MD, PhD
National Mexican Institute of Psychiatry
Mexico City, Mexico
Stefano Pallanti, MD, PhD
University of Florence
Florence, Italy
Katharine Phillips, MD
Brown Medical School
Providence, RI
Harold A. Pincus, MD
Columbia University
New York, NY
Scott L. Rauch, MD
Massachusetts General Hospital
Charlestown, MA
Alan F. Schatzberg, MD
Stanford University School of Medicine
Stanford, CA
Thomas E. Schlaepfer, MD
University of Bonn
Bonn, Germany
Stephen M. Stahl, MD, PhD
University of California, San Diego
La Jolla, CA
Norman Sussman, MD
New York University Medical School
New York, NY
Michael E. Thase, MD
University of Pennsylvania School of Medicine
Philadelphia, PA
Madhukar H. Trivedi, MD
University of Texas Southwestern Medical
Center
Dallas, TX
Karen Dineen Wagner, MD, PhD
The University of Texas Medical Branch
Galveston, TX
Herman G.M. Westenberg, MD
University Hospital Utrecht
Utrecht, The Netherlands
Stuart C. Yudofsky, MD
Baylor College of Medicine
Houston, TX

PUBLICATION STAFF

CEO & PUBLISHER

Darren L. Brodeur

VP, MANAGING EDITOR

Christopher Naccari

VP, HUMAN RESOURCES

Kimberly A. Brodeur

SENIOR GLOBAL ACCOUNT DIRECTOR

Richard Ehrlich

GLOBAL ACCOUNT MANAGER

Evan Frieder

SENIOR EDITORS

Dena Croog
José Ralat

ASSOCIATE EDITOR

Lonnie Stoltzfoos

ASSISTANT EDITOR

Carlos Perkins, Jr.

SENIOR ACQUISITIONS EDITOR

Lisa Arrington

ACQUISITIONS EDITOR

Virginia Jackson

CME DEVELOPMENT MANAGERS

Annette Schwind
Shelley Wong

ASSISTANT—CME ADMINISTRATION

Sonny Santana

ART DIRECTOR

Derek Oscarson

GRAPHIC DESIGNER

Michael J. Vodilko

CHIEF FINANCIAL OFFICER

John Spano

ACCOUNTING INTERN

Stephanie Spano

SALES & EVENT COORDINATOR

Kimberly Schneider

INFORMATION TECHNOLOGY

Clint Bagwell Consulting

CORPORATION COUNSEL

Lawrence Ross, Esq.
Bressler, Amery, and Ross

MBL
communications

Publishers of **PRIMARY PSYCHIATRY**
The Largest Peer-Reviewed Psychiatric Journal in the Nation

CNS SPECTRUMS
The International Journal of Neuropsychiatric Medicine

Psychiatry Weekly
The Leading News Service From Primary Psychiatry and Psychiatric Medicine

ADS
ALZHEIMER'S DISEASE SUMMIT

INTERNATIONAL ANXIETY DISORDERS SYMPOSIUM AMSTERDAM, THE NETHERLANDS MAY 27-28, 2009

www.adsymposia.org


NEW!

Presentations

- Advances in PTSD
- Advancing drug development in anxiety disorders
- Cognition in anxiety disorders
- Comorbidity of anxiety disorders
- Current trends in OCD treatment
- DSM-V and ICD-10 issues of anxiety disorders
- Visualizing anxiety disorders

Speakers

- Christer Allgulander, Sweden
- David Baldwin, UK
- Wim van den Brink, Netherlands
- Sam Chamberlain, UK
- Damiaan Denys, Netherlands
- Naomi Fineberg, UK
- Christian Grillon, USA
- Dirk Hermans, Belgium
- Eric Hollander, USA
- David Mataix-Cols, UK
- David Nutt, UK
- Miranda Olf, Netherlands
- Michael Otto, USA
- Stefano Pallanti, Italy
- Katharine Phillips, USA
- Predrag Petrovic, Sweden
- Dan Stein, South Africa
- Murray Stein, USA
- Dick Veltman, Netherlands
- Hans-Ulrich Wittchen, Germany
- Joseph Zohar, Israel



International
Anxiety Disorders Symposium



 **ABN-AMRO**

Main sponsor

AstraZeneca
PSYCHIATRY

EDITOR'S LETTER

- 116 Optimal Dosing of Desvenlafaxine, New Insights in Gambling and Anorexia, and Caffeine-Induced Psychosis**

Eric Hollander, MD, *Institute of Clinical Neuroscience*

COMMUNIQUE

- 118 Computerized Neuropsychological Assessments: Pros and Cons**

PEARLS IN CLINICAL NEUROSCIENCE

- 122 Bipolar Disorder: Emotional Dysregulation and Neuronal Vulnerability**

Dan J. Stein, MD, PhD, Neil Horn, MB ChB, FRCPsych, Rajkumar Ramesar, PhD, *University of Cape Town*; and Jonathan Savitz, PhD, *National Institute of Mental Health*

CASE REPORTS

- 127 Caffeine-Induced Psychosis**

Dawson W. Hedges, MD, Fu Lye Woon, MA, *Brigham Young University*; and Scott P. Hoopes, MD, *University of Utah School of Medicine* and Marc N. Potenza, MD, PhD, *Yale University School of Medicine*

- 156 Anorexia Nervosa in Identical Triplets**

Mae S. Sokol, MD, *Creighton University School of Medicine*; Anna K. Carroll, BA, *University of Washington's Public Health Nutrition Program*; Denise M. Heebink, MD, *Weill Cornell Medical College*; Kristina M. Hoffman-Rieken, BS, RD, LMNT, *Creighton University School of Medicine*; Christine S. Goudge, MD, *University of Minnesota*; and Douglas D. Ebers, MD, *University of Nebraska College of Medicine*

ORIGINAL RESEARCH

- 132 Disordered Gambling Among Racial and Ethnic Groups in the US: Results From the National Epidemiologic Survey on Alcohol and Related Conditions**

Analucia A. Alegria, BA, *Columbia University*; Nancy M. Petry, PhD, *University of Connecticut Mental Health Center*; Deborah S. Hasin, PhD, Shang-Min Liu, MA, *Columbia University*; Bridget F. Grant, PhD, PhD, *National Institute on Alcohol Abuse and Alcoholism*; and Carlos Blanco, MD, PhD, *Columbia University*

- 144 Integrated Analysis of the Efficacy of Desvenlafaxine Compared with Placebo in Patients with Major Depressive Disorder**

Michael E. Thase, MD, *University of Pennsylvania School of Medicine*; Susan G. Kornstein, MD, *Virginia Commonwealth University*; Jean-Michel Germain, PhD, *Wyeth Research France*; Qin Jiang, MS, Christine Guico-Pabia, MD, MBA, MPH, and Philip T. Ninan, MD, *Wyeth Pharmaceuticals*

CME EXPERT REVIEW SUPPLEMENT**Pharmacologic and Therapeutic Strategies in Treatment-Resistant Depression**

John P. O'Reardon, MD, Michael E. Thase, MD, and George I. Papakostas, MD



CME3

CNS Spectrums (ISSN 1092-8529) is published monthly by MBL Communications, Inc., 333 Hudson Street, 7th Floor, New York, NY 10013. Application to mail Periodicals postage rates is pending at New York, NY, and additional mailing offices. POSTMASTER: Send address changes to *CNS Spectrums*, 333 Hudson Street, 7th Floor, New York, NY 10013.

One-year subscription rates: domestic \$120; foreign \$195; in-training \$85. For subscriptions: Tel: 212-328-0800; Fax: 212-328-0600; Web: www.cns-spectrums.com. Single issues: \$15 – E-mail ks@mbcommunications.com

Opinions and views expressed by authors are their own and do not necessarily reflect the views of the publisher, MBL Communications, Inc., *CNS Spectrums*, LLC, or the editorial advisory board.

This month's issue of *CNS Spectrums*, as well as a host of educational resources, enduring materials, and archived issues, is available at www.cns-spectrums.com.

Advertisements in *CNS Spectrums* are accepted on the basis of adherence to ethical medical standards, but acceptance does not imply endorsement by *CNS Spectrums* or the publisher.

CNS Spectrums is a registered trademark of *CNS Spectrums*, LLC, New York, NY. Permission to reproduce articles in whole or part must be obtained in writing from the publisher.



Copyright © 2009 by MBL Communications, Inc. All rights reserved. Printed in the United States.



DID SHE TELL YOU ABOUT HER POOR METABOLISM?

AmpliChip CYP450 Test

The **first FDA-cleared test** that **reliably detects variations** in the **CYP2D6 and CYP2C19 genes** with greater than **99% accuracy** for detection and genotype call rate.¹

With the AmpliChip CYP450 Test results, you may achieve improved patient outcomes by using your patients' metabolic profiles as a guide to medication and dosing.

For more information, visit www.amplichip.us.

1. AmpliChip CYP450 Test Package
Insert as of 03/20/2007

AMPLICHIP is a trademark of Roche.
©2007 Roche Diagnostics.
All rights reserved. 472-39211-0108

AMPLI^{CHIP}